1. In Vivo
  2. >>Innovation

Big Pharma's Practice-Changing Data Dominates At ESMO

 
• By Kevin Grogan

Unseasonal showers hit Madrid during the European Society for Medical Oncology congress where most of the major data readouts came from the biggest players in the sector rather than ambitious biotechs. Here, In Vivo looks at three must-see presentations from the prestigious meeting.  

Cancer cell

It is always a good sign when your presentation is interrupted by a standing ovation. This was the fate of Tom Powles, director of Barts Cancer Centre in London, at an ESMO presidential symposium where he gave the detailed results of the Phase III EV-302/KEYNOTE-A39 trial looking at the combination of Seagen Inc. and Astellas Pharma, Inc.'s antibody-drug conjugate Padcev (enfortumab vedotin) and Merck & Co., Inc.'s checkpoint inhibitor Keytruda (pembrolizumab), as front-line therapy in patients with locally advanced or metastatic urothelial carcinoma (UC), which covers almost all bladder cancers.

The combo was the first regimen containing an ADC and an anti-PD-1/L1 agent to gain a US green light in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By Jo Shorthouse

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.